LAVA THERAPEUTICS NV (LVTX) Stock Price, Forecast & Analysis
USA - NASDAQ:LVTX - NL0015000AG6 - Common Stock
LVTX Key Statistics, Chart & Performance
The current stock price of LVTX is 1.7 USD. In the past month the price increased by 11.84%. In the past year, price increased by 8.28%.
LVTX Latest News, Press Relases and Analysis
LVTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.58 | 410.35B | ||
| AMGN | AMGEN INC | 15.36 | 180.89B | ||
| GILD | GILEAD SCIENCES INC | 15.29 | 155.35B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.03 | 111.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.44 | 73.66B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 890.14 | 59.51B | ||
| INSM | INSMED INC | N/A | 40.36B | ||
| NTRA | NATERA INC | N/A | 27.54B | ||
| BIIB | BIOGEN INC | 9.84 | 24.15B | ||
| INCY | INCYTE CORP | 16.42 | 20.58B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.52 | 20.91B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.49 | 14.30B |
Related stock screener links
About LVTX
Company Profile
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Company Info
LAVA THERAPEUTICS NV
Yalelaan 60
Utrecht UTRECHT NL
Employees: 34
Phone: 31630003035
LAVA THERAPEUTICS NV / LVTX FAQ
What does LVTX do?
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
What is the stock price of LAVA THERAPEUTICS NV today?
The current stock price of LVTX is 1.7 USD. The price increased by 6.25% in the last trading session.
Does LAVA THERAPEUTICS NV pay dividends?
LVTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of LVTX stock?
LVTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for LVTX stock?
The Revenue of LAVA THERAPEUTICS NV (LVTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the number of employees for LAVA THERAPEUTICS NV?
LAVA THERAPEUTICS NV (LVTX) currently has 34 employees.
LVTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX is one of the better performing stocks in the market, outperforming 72.13% of all stocks.
LVTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LVTX. The financial health of LVTX is average, but there are quite some concerns on its profitability.
LVTX Financial Highlights
Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -1.05. The EPS decreased by -15.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.12% | ||
| ROE | -190.76% | ||
| Debt/Equity | 0 |
LVTX Forecast & Estimates
7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -17.8% is expected in the next year compared to the current price of 1.7.
For the next year, analysts expect an EPS growth of 7.87% and a revenue growth -100% for LVTX